StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Naphazolin

Naphazoline

HCID 4436
Neue Reaktion
Drucken

Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen

GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
10061-11-7
Standard-SMILES
c1ccc2c(CC3=NCCN3)cccc2c1
InChIKey
CNIIGCLFLJGOGP-UHFFFAOYSA-N
Summenformel
C14H14N2
Durchschnittliche Molmasse
210,27 g/mol
Monoisotopische Masse
210,11569846

Überblick

2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole is a member of naphthalenes.

Namen und Bezeichner

Bevorzugter Name
Naphazoline
IUPAC
2-(naphthalen-1-ylmethyl)-4,5-dihydro-1H-imidazole
Lokaler Name
Naphazolin
Englischer Name
Naphazoline
Summenformel
C14H14N2
Molmasse
210.27

Namen und Synonyme

naphazoline835-31-42-(naphthalen-1-ylmethyl)-4,5-dihydro-1H-imidazoleNafazolinaClearineNafazolinNaphazolinum2-(1-Naphthylmethyl)-2-imidazolineCiba 2020/Ralpha-Naphthylmethyl imidazoline1H-Imidazole, 4,5-dihydro-2-(1-naphthalenylmethyl)-DTXSID3048449
Weitere Namen anzeigen
NAPHAZOLINE HCLNAFAZOLINENaphazoline-d42-(1-NAPHTHYLMETHYL)-2-IMIDAZOLINE HYDROCHLORIDEAntanImidinPrivineSanorinRhinazineciba2020/r
H231GF11BVDTXCID90198485Tele StullnAK ConVasoconstrictor PensaPensa, VasoconstrictorRefChem:56335naphthizinum (for the nitrate)

Datenbank-Bezeichner

CAS
10061-11-7、835-31-4
PubChem CID
4436
DTXSID
DTXSID3048449
ChEMBL
CHEMBL761
ChEBI
CHEBI:93363

Eigenschaften

Berechnete StruktureigenschaftenWird ergänzt

XLogP
2,1
Polarare Oberfläche (TPSA)
24,4 Ų
H-Brücken-Donoren
1
H-Brücken-Akzeptoren
1
Frei drehbare Bindungen
2
Schwere Atome
16
Formalladung
0
Komplexität
272

Experimentelle und physikochemische Eigenschaften

DrugsPharmaceuticals -> Listed in ZINC15
Animal DrugsPharmaceuticals -> Animal Drugs -> Approved in Taiwan
Physical DescriptionSolid
Collision Cross Section · 2 Einträge

149.6 Ų [M+H]+ [CCS Type: TW; Method: Major Mix IMS/Tof Calibration Kit (Waters)]

147.59 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Physikochemische Eigenschaften

Schmelzpunkt
254 °C · 254 °C
Siedepunkt
339.81 °C · 339.81°C (rough estimate)
Dichte
1.1063 · 1.1063 (rough estimate)
Brechungsindex
1.618 · 1.6180 (estimate)
storage temp.
2 · 2-8°C
pka
10.35 · pKa 10.35 ± 0.02(H2O,t =25,Iundefined) (Uncertain)

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 3 Einträge

This chemical does not meet GHS hazard criteria for 100% (2 of 2) of all reports.

Not Classified

Aggregated GHS information provided per 2 reports by companies from 1 notifications to the ECHA C&L Inventory.

Gefahrenhinweise

Regulatory InformationREACH registered substance: Naphazoline (EC: 212-641-5)
Hazard Classes and CategoriesNot Classified

Sicherheitsdaten

wgk
3
ridadr
UN 2811 6.1/PG 2
RTECS-Nr.
NJ4375000
risk_code
25
hazard_code
T
safety_code
45

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 6 Einträge

R01AA08

S - Sensory organs

R - Respiratory system

R - Respiratory system

QR - Respiratory system

QR - Respiratory system

Protein BindingProtein binding data for naphazoline is unavailable.
PharmacodynamicsNaphazoline is a sympathomimetic alpha adrenergic agonist that acts to vasoconstrict nasal or ocular arterioles, resulting in reduced congestion at the site of administration.
Mechanism of Action · 1 Eintrag

Naphazoline is a vasoconstrictor that functions by stimulating alpha adrenergic receptors in arterioles leading to decreased congestion at the site of administration. Naphazoline causes the release of norepinephrine in sympathetic nerves. Norepinephrine binds to alpha adrenergic receptors and causes vasoconstriction. Naphazoline is also a mild beta adrenergic receptor agonist, which can cause rebound vasodilation after the alpha adrenergic stimulation has ended. Naphazoline's release of norepinephrine also triggers a negative feedback loop which decreases production of norepinephrine, which can lead to rhinitis medicamentosa after long term use when naphazoline is stopped.

Biological Half-LifeHalf life has not been determined but effects last for 4 to 8 hours. Other imidazoline compounds have half lives varying from 2 to 12 hours.
Metabolism/MetabolitesMetabolism data for naphazoline are scarce. Imidazoline compounds undergo some hepatic metabolism but a large fraction of the dose may be excreted unchanged in the urine.
MeSH Pharmacological Classification · 2 Einträge

Drugs that selectively bind to and activate alpha adrenergic receptors.

Drugs designed to treat inflammation of the nasal passages, generally the result of an infection (more often than not the common cold) or an allergy related condition, e.g., hay fever. The inflammation involves swelling of the mucous membrane that lines the nasal passages and results in inordinate mucus production. The primary class of nasal decongestants are vasoconstrictor agents. (From PharmAssist, The Family Guide to Health and Medicine, 1993)

Zugehörige Reaktionen

0
Reaktionsaufzeichnung erstellen
Noch keine zugehörigen Reaktionen

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
UNII
H231GF11BV
EC Number
212-641-5、233-197-9
Nikkaji
J7.133A
Aggregatzustand
Solid
Farbe
White to light yellow
CAS Datenbank
835 · 835-31-4(CAS DataBase Reference)
NIST chemische Informationen
Naphazoline(835-31-4)
Absorption, Distribution and Excretion · 4 Einträge

Absorption data for naphazoline are scarce but imidazoline compounds in general are weakly basic and lipophilic, with high bioavailability from the gastrointestinal tract.

Imidazoline compounds undergo some hepatic metabolism but a large fraction of the dose may be excreted unchanged in the urine. Urinary excretion is higher with more acidic urine.

Distribution data for naphazoline are scarce but imidazoline compounds are distributed throughout the body, and can cross the blood-brain barrier.

Clearance data for naphazoline is unavailable.

Cellular LocationsMembrane

Verwendung und Herstellung

Use ClassificationPharmaceuticals -> Animal Drugs -> Approved in Taiwan

Anwendungen

VerwendenNaphazoline is used in severe rhinitis associated with colds, allergic reactions, and severe and chronic inflammatory conditions, in particular for inflammation of the antrum of Highmore as well as for stopping nosebleeds.

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

MethanolEthanol1,2-Diaminoethan1-Naphthalenol, 4-methylbenzenesulfonate1-NaphthylacetonitrilETHYLENE DIAMINE TOSYLATEETHYLENEDIAMINE MONOHYDRATE1-Naphthylessigsure2-Aminoethanol

Nachgelagerte Produkte

N-(2-AMINOETHYL)-2-(1-NAPHTHYL)ACETAMIDENaphazolinnitrat